Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 33.3% during the fourth quarter, Holdings Channel reports. The fund owned 418,960 shares of the company’s stock after selling 209,550 shares during the quarter. SG Americas Securities LLC’s holdings in Teva Pharmaceutical Industries were worth $9,234,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Coronation Fund Managers Ltd. acquired a new position in Teva Pharmaceutical Industries in the second quarter valued at approximately $1,334,000. American Century Companies Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 12.9% in the 2nd quarter. American Century Companies Inc. now owns 175,178 shares of the company’s stock valued at $2,847,000 after purchasing an additional 20,026 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Teva Pharmaceutical Industries by 23.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,466,704 shares of the company’s stock worth $23,834,000 after buying an additional 274,891 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its position in Teva Pharmaceutical Industries by 26.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 27,643 shares of the company’s stock valued at $449,000 after buying an additional 5,831 shares during the period. Finally, Thrivent Financial for Lutherans increased its holdings in Teva Pharmaceutical Industries by 44.1% in the second quarter. Thrivent Financial for Lutherans now owns 184,293 shares of the company’s stock valued at $2,995,000 after buying an additional 56,388 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $21.75 on Friday. The company has a market cap of $24.64 billion, a P/E ratio of -25.58, a P/E/G ratio of 1.10 and a beta of 0.73. Teva Pharmaceutical Industries Limited has a twelve month low of $11.48 and a twelve month high of $22.80. The company’s 50-day moving average price is $19.53 and its 200-day moving average price is $18.32. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. UBS Group upped their target price on Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus target price of $22.63.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.